The Indian eye-care chain, backed by General Atlantic, could submit documents as early as this month.
ASG is considering issuing about 15% in fresh equity, while the share sale is also expected to include stock from existing investors.
The planned listing would tap public markets for expansion capital and offer a partial exit route for current shareholders.
Could ASG Eye Hospital’s $500 million IPO reshape India’s eye care landscape—or will investor priorities compromise clinical quality and affordability?
As PE-backed hospital chains like ASG expand rapidly, will rural patients truly see better access, or will gaps in care and affordability persist?